ReviewFrontiers in immunology2016
The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 68 citations in OpenAlex.
- High Seroprevalence Rates of Toxoplasma gondii and Neospora caninum in Dogs in the Pantanal Region of Mato Grosso, Brazil.Acta parasitologica · 2026Article
- Concomitant immunity in persistent Leishmania infections: could it represent an evolutionary balance and a vaccine target?Parasites & vectors · 2025Review
- Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis.Frontiers in immunology · 2024Review
- Sex-structured disease transmission model and control mechanisms for visceral leishmaniasis (VL).PloS one · 2024Article
- Article
- Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis.Vaccines · 2023Article
- Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps.Research and reports in tropical medicine · 2023Review
- Following successful anti-leishmanial treatment, neutrophil counts, CD10 expression and phagocytic capacity remain reduced in visceral leishmaniasis patients co-infected with HIV.PLoS neglected tropical diseases · 2022Article
- Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV.Cell reports. Medicine · 2022Article
- Epidemiologic, Clinical and Immunological Consequences of Co-Infections during Canine Leishmaniosis.Animals : an open access journal from MDPI · 2021Review
- Dissecting pathways to thrombocytopenia in a mouse model of visceral leishmaniasis.Blood advances · 2021Article
- Immune response dynamics and Lutzomyia longipalpis exposure characterize a biosignature of visceral leishmaniasis susceptibility in a canine cohort.PLoS neglected tropical diseases · 2021Article
- The IL-33/ST2 Axis in Immune Responses Against Parasitic Disease: Potential Therapeutic Applications.Frontiers in cellular and infection microbiology · 2020Review
- Interleukin-27 Functional Duality BalancesFrontiers in immunology · 2020Review
- Alteration of Clinical Chemistry Parameters Among Visceral Leishmaniasis Patients in Western Tigrai, Ethiopia, 2018/2019: A Comparative Cross-Sectional Study.Infection and drug resistance · 2020Article
- The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.The Journal of infectious diseases · 2019Article
- Review
- Intracellular anti-leishmanial effect of Spergulin-A, a triterpenoid saponin ofInfection and drug resistance · 2019Article
- Antileishmanial activity and immunomodulatory effect ofThe journal of venomous animals and toxins including tropical diseases · 2019Article
- Novel Loci Controlling Parasite Load in Organs of Mice Infected WithFrontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmania is a genus of protozoan parasites that give rise to a range of diseases called Leishmaniasis that affects annually an estimated 1.3 million people from 88 countries. Leishmania donovani and Leishmania (L.) infantum chagasi are responsible to cause the visceral leishmaniasis. The parasite can use assorted strategies to interfere with the host homeostasis to establish persistent infections that without treatment can be lethal. In this review, we highlight the mechanisms involved in the parasite subversion of the host protective immune response and how alterations of host tissue physiology and vascular remodeling during VL could affect the organ-specific immunity against Leishmania parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.